linjc16/ctgov huggingface dataset:
Analysis of Body Mass Index in Central Precocious Puberty Patients Treated With Leuprolide Acetate

Study Overview
=================
Brief Summary
-----------------
Analysis of body mass index in Central Precocious Puberty patients treated with leuprolide acetate

Official Title
-----------------
Analysis of Body Mass Index in Central Precocious Puberty(CPP) Patients Treated With Leuprolide Acetate

Conditions
-----------------
Precocious Puberty, Central

Intervention / Treatment
-----------------
* Drug: Leuprolide


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Child diagnosed with CPP who has a peak-stimulated Lutenizing Hormone(LH) concentration over 5 IU/liter before initiation of therapy Chronological age(CA) at the appearance of pubertal changes less than 8 years in girls and less than 9 years in boys. Tanner stage ≥2 Advanced bone age (Bone Age/Chronological Age >1.1) Able to have the signed written informed consent provided by the patients' parents or legal guardians prior to any study-related procedures Exclusion Criteria: Patient with a peripheral precocious puberty: extrapituitary secretion of gonadotropins or gonadotropin-independent gonadal or adrenal sex steroids secretion Patient with a cerebral tumor requiring a neurosurgery or cerebral irradiation known chronic disease of underlying medical condition Currently on or planning growth hormone treatment Previous Gonadotropin-Releasing Hormone agonist treatment Any patient who in opinion of the investigator should not participate in the study

Ages Eligible for Study
-----------------
Maximum Age: 9 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Leuprolide acetate<br> | Drug: Leuprolide<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline Body Mass Index Standard Deviation Score for Chronological Age at 6 months |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline Body Mass Index Standard Deviation Score for Chronological Age at 3 months |  | 3 months |
Executive Functioning and Mindfulness in Adults With Attention Deficit/Hyperactivity Disorder Imaging

Study Overview
=================
Brief Summary
-----------------
The main purpose of this study is to evaluate changes in brain functioning using an MRI machine following mindfulness meditation training.

Detailed Description
-----------------
The broad objective of this proposal is to identify functional neuroanatomical correlates of changes in executive brain functioning prior to and following an 8-week, group-based mindfulness meditation intervention within a group of 10 adults diagnosed with Attention-deficit/hyperactivity disorder (ADHD). Another group of 10 adults diagnosed with ADHD will be placed in the waitlist condition. Our primary hypothesis is that adults with ADHD in the treatment group will exhibit improved performance on a series of executive functioning tasks and that exposure to task stimuli will correspond to changes in neural functioning following an 8-week, group-based mindfulness intervention. Brain responses will be measured using blood-oxygenation-level-dependent (BOLD) fMRI signal in brain regions associated with emotional and executive processes prior to and following treatment.

Official Title
-----------------
Executive Functioning and Mindfulness in Adults With ADHD Imaging

Conditions
-----------------
Attention-deficit/Hyperactivity Disorder

Intervention / Treatment
-----------------
* Behavioral: Mindfulness Meditation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ages 18-50 years meet DSM-IV criteria for ADHD intellectual functioning ≥ 80 as assessed by an IQ screener generally healthy (i.e., no major medical problems) Exclusion Criteria: major medical condition that would make participation unsafe (e.g., have pacemaker or other metallic implant), uncomfortable (e.g., chronic pain) claustrophobic, or abnormally afraid of closed-in places current drug use

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Mindfulness Meditation|8-week, group-based mindfulness meditation intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change from baseline in blood-oxygenation-level-dependent (BOLD) fMRI signal | Participants will be scanned prior to and following an 8-week group-based mindfulness meditation intervention | baseline and 8-weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Attention-deficit/hyperactivity disorder, executive functioning, mindfulness meditation, magnetic resonance imaging, healthy
A Study of Baked Milk Tolerance to Treat Eosinophilic Esophagtis

Study Overview
=================
Brief Summary
-----------------
This research is being done to see if patients with milk-triggered EoE are able to tolerate baked milk in their diet and if there is a threshold amount of straight milk that is tolerable.

Official Title
-----------------
A Pilot Trial of Baked Milk Introduction in Patients With Milk-triggered Eosinophilic Esophagitis

Conditions
-----------------
Eosinophilic Esophagitis

Intervention / Treatment
-----------------
* Dietary Supplement: Baked Milk


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed with Eosinophilic esophagitis ≥ 15 eosinophils per HPF Going through or completed the six-food elimination diet, with milk only or milk plus one additional food identified as a trigger Exclusion Criteria: Patients with conditions known to be associated with esophageal eosinophilia, including Crohn's disease, Churg-Strauss, achalasia, and hypereosinophilic syndrome Topical swallowed steroids within 8 weeks of study enrollment Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Baked Milk<br>Baked milk introduction into diet | Dietary Supplement: Baked Milk<br>* Participants to regularly eat a baked milk muffin for 6 weeks<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Histological remission | Number of patients in histologic remission at the end of a 6 week trial of baked milk. Histologic remission is defined by <15 eos per HPF on cytosponge. | 6 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Symptomatic remission | Number of patients in symptomatic remission after a 6 week trial of baked milk. Symptomatic remission is defined by EEsAI PRO score of <20 | 6 weeks |
Genetic Determinant of Foveolar Hypoplasia in Parents of Albinos Children

Study Overview
=================
Brief Summary
-----------------
Fovea plana could be the phenoyipic translation of a genetic anomaly in one of the genes identified in albinisme

Official Title
-----------------
Genetic Determinant of Foveolar Hypoplasia in Parents of Albinos Children

Conditions
-----------------
Albinism, Ocular

Intervention / Treatment
-----------------
* Genetic: blood sample for genetic test
* Diagnostic Test: Ophtalmological examination


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: children with albinism father and mother of children with albinism Exclusion Criteria: sign of albinism except fovea plana in father or mother of children with albinism ophthalmological abnormalities making access to the fundus with OCT impossible

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: blood sample for genetic test|detection of pathogenic variants among the 19 genes known to be involved in albinism|
|Diagnostic Test: Ophtalmological examination|measurement of visual acuity, OCT and OCTA|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of genetics variants | among the genes involved in albinism, identification of those presents in parents of children with albinism | 1 month |
OS Anesthesia Followup of All Bariatric Procedures at One Hospital

Study Overview
=================
Brief Summary
-----------------
Database registering demographic patient data, anesthesia and surgery information, post operative recovery and complications if any.

Detailed Description
-----------------
Every patient undergoing a bariatric procedure is entered in the data base after the procedure is finished, based on the information available in the medical records. the study has no end point and keeps collecting data as long as procedures are performed. The data is analyzed intermittent when medical questions arise on quality and outcome changes due to changes in clinical treatment taken in order to improve individual patient care.

Official Title
-----------------
Retrospective Analysis of Anesthesia Delivering for Bariatric Surgery

Conditions
-----------------
Anesthesia Recovery

Intervention / Treatment
-----------------
* Other: anesthesia given as required for surgical procedure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all bariatric procedures Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: anesthesia given as required for surgical procedure|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Postoperative complications first month after surgery. | Clavien-Dindoo classification class 2 to 5 used to describe complications | one month followup |
The Function of Nutrition Rich Vegan Drink on Inflammatory Bowel Disease

Study Overview
=================
Brief Summary
-----------------
The aim of this project, would be to develop a new formula, with high nutrition content on a vegan basis. The investigators expect to produce this novel vegan-based juice product, which does not exist on the marked today. The juice would consist of different selected varieties of vegetables and fruits. Beside the vegetables, the juice will also contain plant oils to increase the calorie level, as well as a protein sources containing amino acids with high anabolic effects. The products will be tested in an intervention study on patients with inflammatory bowel disease.

Official Title
-----------------
The Function of Nutrition Rich Vegan Drink on Inflammatory Bowel Disease

Conditions
-----------------
Recovery

Intervention / Treatment
-----------------
* Dietary Supplement: Vegan drink
* Dietary Supplement: Control


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Between 18 and 85 years old Diagnosed with or show signs of UC or Crohns disease Mild symptoms i.e intestinal symptoms Has had the same medicin the previous week before starting in the study Exclusion Criteria: Food or vegetable allergi Cognitive diseases e.g alzheimers or dementia Has diabetes requiring insulin or GLP-1 analog treatment (NB: No does include T2D patients, taking tablets or other diabetes therapy)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Vegan drink<br>Treatment group | Dietary Supplement: Vegan drink<br>* Vegan based drink containing vegetables, fruits and plant oils. Dose: 500 mL a day<br>|
| Placebo Comparator: Control<br>Placebo group | Dietary Supplement: Control<br>* Placebo drink Dose: 500 mL a day<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Inflammatory factors | F-calprotectin | 3 weeks |
Duloxetine vs. Active Comparator in the Treatment of Patients With Depression

Study Overview
=================
Brief Summary
-----------------
How duloxetine compares to a medication currently available for the treatment of patients diagnosed with depression

Official Title
-----------------
Duloxetine Versus Venlafaxine Extended Release in the Treatment of Major Depressive Disorder

Conditions
-----------------
Depression

Intervention / Treatment
-----------------
* Drug: Duloxetine Hydrochloride
* Drug: Venlafaxine Extended Release


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must be at least 18 years of age Must be diagnosed with depression Must sign informed consent Women who can become pregnant must be using birth control Exclusion Criteria: Previous diagnosis of bipolar disorder, schizophrenia, or other psychotic disorder History of substance abuse or dependence in the last year Patients who are suicidal Frequent or severe allergic reactions with multiple medications

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Duloxetine Hydrochloride|nan|
|Drug: Venlafaxine Extended Release|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The linear measure of global benefit-risk assessment. Benefit defined as remission at endpoint (HAMD 17 total score less than or equal to 7), a virtually symptom-free state. |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HAMD17 Response Rates defined as greater than or equal to 50% reduction in HAMD17 total score from baseline to endpoint. |  |  | 
| HAMD17 Time-to-First Response defined as the visit where a sustained greater than or equal to 30% reduction in the Maier subscale of the HAMD17. |  |  | 
| HAMD17 Remission Rates defined as HAMD17 total score of less than or equal to 7 at endpoint. |  |  | 
| Hamilton Anxiety Rating Scale measures the presence and severity of anxiety. |  |  | 
| Clinical Global Impressions of Severity scale to record severity of illness at the time of assessment. |  |  | 
| Patient's Global Impressions of Improvement scale measures improvement of the patient's symptoms. |  |  | 
| HAMD17 Subscales evaluate severity of psychic and somatic manifestations of anxiety as well as agitation and evaluate dysfunction in mood, work, and sexual activity, as well as overall motor retardation and evaluate initial, middle, and late insomnia. |  |  |
The Effect of Docosahexaenoic Acid Supplementation on Biomarkers of Concussion Over the Course of a Year in Canadian National Rugby Players

Study Overview
=================
Brief Summary
-----------------
Nutrition interventions may present a safe and relatively risk free intervention for protection against subconcussive impacts. Docosahexaenoic acid (DHA, 22:6n-3) is the principal Omega 3 polyunsaturated fatty acid in the brain, playing an integral role in the brain's development and structural integrity. The goal of this study is to determine if supplementation with DHA attenuates blood biomarkers of repetitive head trauma linked to sub-concussive impacts sustained in rugby participation.

Official Title
-----------------
The Effect of Docosahexaenoic Acid Supplementation on Biomarkers of Concussion Over the Course of a Year in Canadian National Rugby Players

Conditions
-----------------
Head Trauma

Intervention / Treatment
-----------------
* Dietary Supplement: Docosahexaenoic Acid (DHA)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Canadian national rugby athletes on 7s and 15s teams Exclusion Criteria: None
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Basic Science
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dietary Supplement<br>Docosahexaenoic Acid (DHA) | Dietary Supplement: Docosahexaenoic Acid (DHA)<br>* Daily administration of docosahexaenoic Acid (DHA). 2 grams of DHA liquid concentrate administered per day throughout trial period.<br>* Other names: Brain Armor DHA Liquid Concentrate;|
| No Intervention: No Intervention<br>No Docosahexaenoic Acid supplementation | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Blood concentration of neurofilament light protein | Concentrations of neuronally derived proteins measured in blood | 12 times throughout course of 1 year |
Triton Fundus Autofluorescence and Fluorescein Angiography

Study Overview
=================
Brief Summary
-----------------
Compare the image quality of the fundus autofluorescence and fluorescein angiography

Detailed Description
-----------------
The objectives of this study are to: Compare the image quality of the fundus autofluorescence (FAF) photographs between DRI OCT Triton (plus) and TRC-50DX retinal camera. Compare the image quality of the fluorescein angiography (FA) photographs between DRI OCT Triton (plus) and TRC-50DX retinal camera.

Official Title
-----------------
Topcon DRI OCT Triton (Plus) Fundus Autofluorescence and Fluorescein Angiography Image Quality Evaluation Study

Conditions
-----------------
Medical Need for Fluorescein Angiography Imaging

Intervention / Treatment
-----------------
* Device: Topcon DRI OCT Triton (plus)
* Device: TRC-50DX retinal camera


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Subjects must be at least 18 years of age Subjects able to understand the written informed consent and willing to participate as evidenced by signing the informed consent Subjects who consent to, via clinic's standard FA consent form, and will undergo dye injection for FA imaging at the clinic visit based on medical need Exclusion Criteria Subjects unable to tolerate ophthalmic imaging Subjects with ocular media not sufficiently clear to obtain acceptable fundus images Patients with ocular motility dysfunction

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Medical need for FA imaging<br>Subjects deemed to have a medical need for FA imaging will be imaged on the Topcon DRI OCT Triton (plus) and TRC-50DX retinal camera | Device: Topcon DRI OCT Triton (plus)<br>* The Topcon DRI OCT Triton (plus) is an OCT with a fundus camera used for diagnostic purposes<br>Device: TRC-50DX retinal camera<br>* The TRC-50DX retinal camera is a fundus camera used for diagnostic purposes<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Fundus autofluorescence image quality | Comparison of DRI OCT Triton (plus) and TRC-50DX photographs | 1 Minute | 
| Fluorescein angiography image quality at 120 seconds to 300 seconds after dye injection | Comparison of DRI OCT Triton (plus) and TRC-50DX photographs | 120 seconds to 300 seconds | 
| Fluorescein angiography image quality at greater than 300 seconds after dye injection | Comparison of DRI OCT Triton (plus) and TRC-50DX photographs | greater than 300 seconds |